Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

NCT05253911 ·Status: COMPLETED

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

NCT01983501 ·Status: COMPLETED ·Phase: PHASE1

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

NCT00944047 ·Status: COMPLETED ·Phase: PHASE2

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

NCT06983691 ·Status: NOT_YET_RECRUITING ·Phase: NA

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

NCT01548677 ·Status: COMPLETED ·Phase: PHASE2

Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer

NCT02424682 ·Status: COMPLETED

A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer

NCT02443467 ·Status: COMPLETED

Adj TC + Herceptin Early Stage Breast Cancer

NCT00493649 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study

NCT06162559 ·Status: RECRUITING ·Phase: PHASE1

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

NCT03846583 ·Status: WITHDRAWN ·Phase: PHASE1

A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

NCT02748213 ·Status: COMPLETED ·Phase: PHASE2

Observation Only Study Involving Participants Enrolled in the CHAT Trial

NCT01038466 ·Status: UNKNOWN

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

NCT02162667 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

NCT07281001 ·Status: RECRUITING ·Phase: NA

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

NCT00726180 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia

NCT05905939 ·Status: COMPLETED

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

NCT00047255 ·Status: COMPLETED ·Phase: PHASE3

Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States

NCT07342309 ·Status: ACTIVE_NOT_RECRUITING

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

NCT00136539 ·Status: COMPLETED ·Phase: PHASE2

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

NCT00005635 ·Status: COMPLETED ·Phase: PHASE2

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

NCT03644186 ·Status: COMPLETED ·Phase: PHASE2

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

NCT07198724 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

NCT03521245 ·Status: UNKNOWN

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

NCT03684863 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2